
Vanderbilt plans a ketamine safety study for adults over 60 with depression and cognitive impairment. Read about its design and evidence limits.

On October 22, 2026, Vanderbilt University Medical Center announced an Alzheimer’s Association-funded study of intravenous (IV) ketamine’s safety and tolerability in people with depression and cognitive impairment. The funding went to geriatric psychiatrist Patricia Andrews for research involving major depressive disorder alongside mild cognitive impairment (MCI) or mild Alzheimer’s dementia.
The study is called KeTADiD, short for “Ketamine for Treatment of Alzheimer’s Disease related Depression.” Its central question concerns safety and tolerability in a specific group of older adults.
Vanderbilt says the study is designed for men and women over 60 who have major depressive disorder and either MCI or mild dementia. Participants must also have biomarker evidence of Alzheimer’s disease pathology. That requirement makes the intended study population more specific than older adults who report memory concerns alone.
According to Vanderbilt, participation is planned to last 10-14 weeks and include:
The infusions are planned twice weekly for two weeks. These details describe a research schedule with monitoring and follow-up, not a treatment plan for readers to follow.
The placebo comparison is a notable part of the design. It gives researchers a comparison within the study rather than relying only on changes observed after ketamine infusions.
Andrews described depression as common in Alzheimer’s-related conditions and said it may increase the risk of cognitive decline. She suggested that effective depression treatment could benefit quality of life and function. Those concerns form the rationale for studying this population.
Vanderbilt’s announcement says depression in Alzheimer’s disease-related disorders is currently treated with selective serotonin reuptake inhibitors and norepinephrine reuptake inhibitors. Andrews described their effectiveness in this setting as limited.
The research therefore brings together two concerns: depression care and cognitive impairment. Its starting point is whether this intervention is tolerable for people living with both.
The immediate practical change is a planned research opportunity for a defined group of patients. For someone facing depression alongside cognitive concerns, the most relevant route is an individualized clinical evaluation.
Vanderbilt says its Memory and Aging Clinic can provide that evaluation for adults over 60. When appropriate, the clinic can also connect patients with research opportunities. Personal decisions about depression care belong with a qualified clinician who can assess the individual situation.
A discussion with a care team can focus on questions such as:
The announced schedule also gives patients and families a clearer sense of the commitment involved. Participation extends beyond infusion visits to include follow-up contact. Those practical details deserve attention when discussing research with the study team.
For clinicians, the announcement identifies a specific research question to discuss with suitable patients: tolerability of monitored IV ketamine in the setting of depression and Alzheimer’s-related cognitive impairment.
Readers seeking broader background can also turn to FitBrainLab’s coverage of how memory changes with age. Its discussion of the evidence connecting diet and mood offers a separate perspective on questions about cognitive health and depression.
The earlier findings described by Vanderbilt are reasons for further research, not proof that ketamine works in this population. Keeping each type of evidence separate helps prevent a promising observation from becoming a treatment claim.
According to Vanderbilt, an earlier pilot study of repeated IV ketamine in adults over 60 reported improvements in depression and executive function. Another pilot reported improved depression after one infusion in patients with MCI.
Both studies were open label and neither compared ketamine with placebo. Vanderbilt describes their findings as preliminary and says they do not establish efficacy. KeTADiD’s placebo comparison is a useful design difference, but the announcement itself contains no results from the planned study.
Andrews also pointed to reports of improvement in depressive symptoms as early as two hours after infusion in younger adults with depression. She said improvement may continue for several days. Those observations concern younger adults and do not establish the same response in people with MCI or Alzheimer’s dementia.
A headline about rapid relief should therefore stay tied to the population in which that relief was reported. The speed of a response in one group does not answer the safety question being asked in another.
Vanderbilt identifies temporary blood-pressure increases and confusion as potential risks. The announcement says both resolve after the infusion. That description is not a finding that ketamine is safe overall for older adults with cognitive impairment; safety and tolerability are what the study is being designed to assess.
The study is also not described as a test of Alzheimer’s prevention or memory preservation in healthy older adults. Its population has major depressive disorder together with MCI or mild dementia and biomarker evidence of Alzheimer’s pathology.
Improvement in depression, a change in executive function and prevention of cognitive decline are different claims. The earlier pilot findings should not be expanded into evidence that ketamine protects memory or changes the course of Alzheimer’s disease.
Vanderbilt says enrollment was slated to begin in December 2026. The announcement offers interested people a registry so they can be notified when enrollment opens.
If KeTADiD indicates that ketamine is safe for this population, Vanderbilt describes a larger multisite randomized controlled trial as a possible next step. That trial could examine:
That sequence matters. The planned safety study and a possible later trial serve different purposes, with the later stage asking broader questions about benefit.
The announcement provides an enrollment plan rather than a date for routine clinical use. Its proposed next step remains conditional on what the safety research shows. Joining a notification registry is a way to hear about enrollment, not a conclusion about whether participation suits a particular person.
The value of this development lies in the question being asked. Vanderbilt is preparing to study tolerability in people whose depression and cognitive impairment make their care needs specific.
For the long-term direction of cognitive health research, that careful sequence deserves attention. Depression relief, daily functioning and cognition each merit study on their own terms. Progress means measuring those outcomes clearly rather than treating them as interchangeable.
For readers, the useful takeaway is a research opportunity to discuss within individualized care. The announcement advances a question worth answering without supplying the answer in advance.
People facing depression and memory concerns rely on their clinical team for care decisions; FitBrainLab’s role is to make the surrounding research easier to judge. FitBrainLab addresses fear stirred by alarmist dementia coverage with evidence-led explanations for adults 60+, helping readers weigh a study without treating its headline as a prediction about their future.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.



Build habits that support memory, focus and a curious, connected life.
Read the Blog